{"id":"W2143743735","doi":"10.1200/jco.2007.14.9930","title":"Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2963,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Bevacizumab; Medicine; Oxaliplatin; FOLFOX; Folinic acid; Internal medicine; Colorectal cancer; Oncology; Capecitabine; Clinical endpoint; Chemotherapy; Placebo; Hazard ratio; Progression-free survival; Surgery; Randomized controlled trial; Cancer; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002346284,0.001454065,0.003273105,0.0005358372,0.0003781448,0.001301826,0.001022422,0.00173196,0.00411129],"category_scores_gemma":[0.001700549,0.0007831574,0.001544145,0.000614836,0.001124878,0.0008167692,0.0003863775,0.002349879,0.0007631545],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001122926,"about_ca_system_score_gemma":0.00165285,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009825545,"about_ca_topic_score_gemma":0.002858041,"domain_scores_codex":[0.999006,0.0006085928,0.00004933999,0.0001287725,0.00009596658,0.0001114261],"domain_scores_gemma":[0.9990342,0.0002167275,0.0002555952,0.0000693472,0.00006744283,0.0003567423],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9409665,0.02153045,0.0009437883,0.0008912999,0.001393293,0.00007729983,0.00004971489,0.0005513667,0.005887782,0.00008662324,0.0009600062,0.02666187],"study_design_scores_gemma":[0.8990873,0.09830515,0.0009934601,0.00003007661,0.0003524858,0.00003540347,0.000007860916,0.0003702179,0.000298949,0.00004549448,0.0004647953,0.0000088584],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9834124,0.007655781,0.0008734933,0.0007160083,0.0006110051,0.004603819,0.0006331938,0.0001228493,0.001371464],"genre_scores_gemma":[0.9800152,0.006176476,0.002342877,0.001245621,0.0007899663,0.006121652,0.001052889,0.0000340009,0.002221186],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00411129,"threshold_uncertainty_score":0.01375365,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1003262096290122,"score_gpt":0.4668804551886769,"score_spread":0.3665542455596647,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}